{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T06:00:58Z","timestamp":1774418458312,"version":"3.50.1"},"reference-count":99,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T00:00:00Z","timestamp":1681862400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Topical treatments are essential approaches to skin diseases but are associated with poor adherence. Topical vehicles have the primary purpose of ensuring drug effectiveness (by modulating drug stability and delivery, as well as skin properties) but have a marked impact on treatment outcomes as they influence patient satisfaction and, consequently, adherence to topical treatments. There is also a wide variety of vehicles available for topical formulations, which can complicate the decisions of clinicians regarding the most appropriate treatments for specific skin disorders. One of the possible strategies to improve topical-treatment adherence is the implementation of patient-centric drug-product design. In this process, the patient\u2019s needs (e.g., those related to motor impairment), the needs associated with the disease (according to the skin lesions\u2019 characteristics), and the patient\u2019s preferences are taken into consideration and translated into a target product profile (TPP). Herein, an overview of topical vehicles and their properties is presented, along with a discussion of the patient-centric design of topical dermatological medicines and the proposal of TPPs for some of the most common skin diseases.<\/jats:p>","DOI":"10.3390\/ph16040617","type":"journal-article","created":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T02:01:11Z","timestamp":1681956071000},"page":"617","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Patient-Centric Design of Topical Dermatological Medicines"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0258-9472","authenticated-orcid":false,"given":"Rita","family":"Oliveira","sequence":"first","affiliation":[{"name":"FP-BHS\u2014Biomedical and Health Sciences Research Unit, FFP-I3ID\u2014Instituto de Investiga\u00e7\u00e3o, Inova\u00e7\u00e3o e Desenvolvimento, Faculdade de Ci\u00eancias da Sa\u00fade, Universidade Fernando Pessoa, Rua Carlos da Maia 296, 4200-150 Porto, Portugal"},{"name":"UCIBIO\u2014Applied Molecular Biosciences Unit, MedTech, Laboratory of Pharmaceutical Technology, Department of Drug Sciences, Faculty of Pharmacy, University of Porto, Rua Jorge Viterbo de Ferreira 228, 4050-313 Porto, Portugal"},{"name":"Associate Laboratory i4HB\u2014Institute for Health and Bioeconomy, Faculty of Pharmacy, University of Porto, Rua Jorge Viterbo de Ferreira 228, 4050-313 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1498-048X","authenticated-orcid":false,"given":"Isabel F.","family":"Almeida","sequence":"additional","affiliation":[{"name":"UCIBIO\u2014Applied Molecular Biosciences Unit, MedTech, Laboratory of Pharmaceutical Technology, Department of Drug Sciences, Faculty of Pharmacy, University of Porto, Rua Jorge Viterbo de Ferreira 228, 4050-313 Porto, Portugal"},{"name":"Associate Laboratory i4HB\u2014Institute for Health and Bioeconomy, Faculty of Pharmacy, University of Porto, Rua Jorge Viterbo de Ferreira 228, 4050-313 Porto, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2023,4,19]]},"reference":[{"key":"ref_1","unstructured":"Costa, E., Giardini, A., and Monaco, A. (2017). Adherence to Medical Plans for Active and Healthy Ageing, Nova Science Publishers, Incorporated."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1159\/000329026","article-title":"Adherence in the treatment of psoriasis: A systematic review","volume":"222","author":"Augustin","year":"2011","journal-title":"Dermatology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1159\/000332847","article-title":"Acne management in Japan: Study of patient adherence","volume":"223","author":"Miyachi","year":"2011","journal-title":"Dermatology"},{"key":"ref_4","first-page":"397","article-title":"A review of patient adherence to topical therapies for treatment of atopic dermatitis","volume":"96","author":"Snyder","year":"2015","journal-title":"Cutis"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s40257-017-0272-2","article-title":"Development and Validation of a Novel Questionnaire for Adherence with Topical Treatments in Psoriasis (QATOP)","volume":"18","author":"Teixeira","year":"2017","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/jdv.15252","article-title":"Treatment use and satisfaction among patients with psoriasis and psoriatic arthritis: Results from the NORdic PAtient survey of Psoriasis and Psoriatic arthritis (NORPAPP)","volume":"33","author":"Tveit","year":"2019","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1468-3083.2011.04440.x","article-title":"Patient preferences for psoriasis treatments: Impact of treatment experience","volume":"27","author":"Schaarschmidt","year":"2013","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1468-3083.2005.01329.x","article-title":"How patients experience psoriasis: Results from a European survey","volume":"19","author":"Adjadj","year":"2005","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jaad.2005.12.021","article-title":"Determining the relative importance of patient motivations for nonadherence to topical corticosteroid therapy in psoriasis","volume":"55","author":"Brown","year":"2006","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Teixeira, A., Teixeira, M., Almeida, V., Gaio, R., Torres, T., Magina, S., Cunha, C., Sousa Lobo, J.M., and Almeida, I.F. (2021). Does the Vehicle Matter? Real-World Evidence on Adherence to Topical Treatment in Psoriasis. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13101539"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.ad.2012.12.005","article-title":"Adherence and Patient Satisfaction With Topical Treatment in Psoriasis, and the Use, and Organoleptic Properties of Such Treatments: A Delphi Study With an Expert Panel and Members of the Psoriasis Group of the Spanish Academy of Dermatology and Venereology","volume":"104","author":"Puig","year":"2013","journal-title":"Actas Dermo-Sifiliogr\u00e1ficas"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s13555-016-0119-4","article-title":"Patient Preferences for Topical Psoriasis Treatments are Diverse and Difficult to Predict","volume":"6","author":"Iversen","year":"2016","journal-title":"Dermatol. Ther."},{"key":"ref_13","unstructured":"Council of Europe (2019). European Pharmacopoeia, 10th Edition 2020, Directorate for the Quality of Medicines and HealthCare of the Council of Europe (EDQM)."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1208\/s12249-018-1246-2","article-title":"Mechanical Properties of Topical Anti-Psoriatic Medicines: Implications for Patient Satisfaction with Treatment","volume":"20","author":"Teixeira","year":"2019","journal-title":"AAPS PharmSciTech"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Swarbrick, J. (2007). Encyclopedia of Pharmaceutical Technology, CRC Press. [3rd ed.].","DOI":"10.1201\/b21612"},{"key":"ref_16","unstructured":"Taylor, K.M.G., and Aulton, M.E. (2021). Aulton\u2019s Pharmaceutics: The Design and Manufacture of Medicines, Elsevier. [6th ed.]."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3139\/113.110405","article-title":"An Overview of Novel Surfactants for Formulation of Cosmetics with Certain Emphasis on Acidic Active Substances","volume":"53","author":"Lukic","year":"2016","journal-title":"Tenside Surfactants Deterg."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"33004","DOI":"10.1039\/D1RA04968B","article-title":"Scientific information about sugar-based emulsifiers: A comprehensive review","volume":"11","author":"Pal","year":"2021","journal-title":"RSC Adv."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.jconrel.2013.06.030","article-title":"Recent expansions in an emergent novel drug delivery technology: Emulgel","volume":"171","author":"Ajazuddin","year":"2013","journal-title":"J. Control. Release"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.cis.2006.11.023","article-title":"Silicone emulsions","volume":"128\u2013130","author":"Somasundaran","year":"2006","journal-title":"Adv. Colloid Interface Sci."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/ics.12800","article-title":"A comparison between silicone-free and silicone-based emulsions: Technological features and in vivo evaluation","volume":"44","author":"Mancuso","year":"2022","journal-title":"Int. J. Cosmet. Sci."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Ohsedo, Y. (2022). N-Alkylhydantoins as New Organogelators and Their Ability to Create Thixotropic Mixed Molecular Organogels. Gels, 8.","DOI":"10.3390\/gels8100638"},{"key":"ref_23","first-page":"1215","article-title":"Physicochemical, rheological and antifungal evaluation of miconazole nitrate organogels for topical delivery","volume":"35","author":"Ambreen","year":"2022","journal-title":"Pak. J. Pharm. Sci."},{"key":"ref_24","first-page":"325","article-title":"Preparation and Evaluation of Pluronic Lecithin Organogels in Cosmetics","volume":"72","author":"Yoon","year":"2021","journal-title":"J. Cosmet. Sci."},{"key":"ref_25","first-page":"s99","article-title":"Vehicles Always Matter","volume":"18","author":"Kircik","year":"2019","journal-title":"J. Drugs Dermatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ejpb.2021.07.012","article-title":"Foams as unique drug delivery systems","volume":"167","author":"Hoc","year":"2021","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/j.1610-0387.2007.06321.x","article-title":"Galenics of dermal products--vehicles, properties and drug release","volume":"5","author":"Daniels","year":"2007","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/j.1529-8019.2012.01458.x","article-title":"Conventional topical delivery systems","volume":"24","author":"Weiss","year":"2011","journal-title":"Dermatol. Ther."},{"key":"ref_29","first-page":"1431","article-title":"Principles and approaches for optimizing therapy with unique topical vehicles","volume":"13","author":"Rosen","year":"2014","journal-title":"J. Drugs Dermatol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1177\/1203475417743234","article-title":"A Guide to Topical Vehicle Formulations","volume":"22","author":"Mayba","year":"2018","journal-title":"J. Cutan. Med. Surg."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Barnes, T.M., Mijaljica, D., Townley, J.P., Spada, F., and Harrison, I.P. (2021). Vehicles for Drug Delivery and Cosmetic Moisturizers: Review and Comparison. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13122012"},{"key":"ref_32","unstructured":"EMA (2023, February 20). Reflection Paper on the Use of Extrapolation in the Development of Medicines for Paediatrics (EMA\/189724\/2018). Available online: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/adopted-reflection-paper-use-extrapolation-development-medicines-paediatrics-revision-1_en.pdf."},{"key":"ref_33","unstructured":"EMA (2023, February 20). Guideline on Pharmaceutical Development of Medicines for Paediatric Use (EMA\/CHMP\/QWP\/805880\/2012 Rev.2). Available online: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-pharmaceutical-development-medicines-paediatric-use_en.pdf."},{"key":"ref_34","unstructured":"EMA (2023, February 20). Reflection paper on the pharmaceutical development of medicines for use in the older population (EMA\/CHMP\/QWP\/292439\/2017). Available online: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/reflection-paper-pharmaceutical-development-medicines-use-older-population-first-version_en.pdf."},{"key":"ref_35","unstructured":"FDA (2023, February 20). Patient-Focused Drug Development: Methods to Identify What Is Important to Patients, Available online: https:\/\/www.fda.gov\/media\/131230\/download."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/MLR.0000000000000273","article-title":"Patient-Focused Drug Development: A New Direction for Collaboration","volume":"53","author":"Perfetto","year":"2015","journal-title":"Med. Care"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s40900-018-0093-3","article-title":"Enhancing the incorporation of the patient\u2019s voice in drug development and evaluation","volume":"4","author":"Chalasani","year":"2018","journal-title":"Res. Involv. Engagem."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s40900-022-00364-8","article-title":"Practices of patient engagement in drug development: A systematic scoping review","volume":"8","author":"Zvonareva","year":"2022","journal-title":"Res. Involv. Engagem."},{"key":"ref_39","unstructured":"ICH (2023, February 20). Proposed ICH guideline work to advance patient focused drug development. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-reflection-paper-proposed-ich-guideline-work-advance-patient-focused-drug-development_en.pdf."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1208\/s12248-016-9938-6","article-title":"Defining Patient Centric Pharmaceutical Drug Product Design","volume":"18","author":"Stegemann","year":"2016","journal-title":"AAPS J."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1111\/bcp.14388","article-title":"Challenges and opportunities to include patient-centric product design in industrial medicines development to improve therapeutic goals","volume":"86","author":"Timpe","year":"2020","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.xphs.2023.01.029","article-title":"Patient-Centric Product Development: A Summary of Select Regulatory CMC and Device Considerations","volume":"112","author":"Algorri","year":"2023","journal-title":"J. Pharm. Sci."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Ogbonna, J.D.N., Cunha, E., Attama, A.A., Ofokansi, K.C., Ferreira, H., Pinto, S., Gomes, J., Marx, \u00cd.M.G., Peres, A.M., and Lobo, J.M.S. (2022). Overcoming Challenges in Pediatric Formulation with a Patient-Centric Design Approach: A Proof-of-Concept Study on the Design of an Oral Solution of a Bitter Drug. Pharmaceuticals, 15.","DOI":"10.3390\/ph15111331"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Shariff, Z., Kirby, D., Missaghi, S., Rajabi-Siahboomi, A., and Maidment, I. (2020). Patient-Centric Medicine Design: Key Characteristics of Oral Solid Dosage Forms that Improve Adherence and Acceptance in Older People. Pharmaceutics, 12.","DOI":"10.3390\/pharmaceutics12100905"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1007\/s12247-019-09407-2","article-title":"Future Perspectives for Patient-Centric Pharmaceutical Drug Product Design with Regard to Solid Oral Dosage Forms","volume":"15","author":"Drumond","year":"2020","journal-title":"J. Pharm. Innov."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Oliveira, R.S., da Silva, D.F., Mota, S., Garrido, J., Garrido, E.M., Lobo, J.M.S., and Almeida, I.F. (2022). Design of an Emulgel for Psoriasis Focused on Patient Preferences. Appl. Sci., 12.","DOI":"10.3390\/app12073260"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"82","DOI":"10.3389\/fmed.2019.00082","article-title":"Patient Preference Studies During Early Drug Development: Aligning Stakeholders to Ensure Development Plans Meet Patient Needs","volume":"6","author":"Cook","year":"2019","journal-title":"Front. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ejpb.2022.06.006","article-title":"Rational and practical considerations to guide a target product profile for patient-centric drug product development with measurable patient outcomes\u2014A proposed roadmap","volume":"177","author":"Stegemann","year":"2022","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1159\/000082572","article-title":"The mystical effects of dermatological vehicles","volume":"210","author":"Surber","year":"2005","journal-title":"Dermatology"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1080\/09546634.2020.1789050","article-title":"Vehicles for atopic dermatitis therapies: More than just a placebo","volume":"33","author":"Danby","year":"2022","journal-title":"J. Dermatol. Treat."},{"key":"ref_51","first-page":"567","article-title":"Measuring the effects of topical moisturizers on changes in stratum corneum thickness, water gradients and hydration in vivo","volume":"159","author":"Crowther","year":"2008","journal-title":"Br. J. Dermatol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"491","DOI":"10.2147\/CCID.S177697","article-title":"Skin hydration is significantly increased by a cream formulated to mimic the skin\u2019s own natural moisturizing systems","volume":"11","author":"Spada","year":"2018","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1111\/ced.15141","article-title":"Different types of emollient cream exhibit diverse physiological effects on the skin barrier in adults with atopic dermatitis","volume":"47","author":"Danby","year":"2022","journal-title":"Clin Exp. Dermatol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.clindermatol.2011.08.015","article-title":"Effect of moisturizers on epidermal barrier function","volume":"30","year":"2012","journal-title":"Clin. Dermatol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.clindermatol.2011.08.018","article-title":"New treatments for restoring impaired epidermal barrier permeability: Skin barrier repair creams","volume":"30","author":"Draelos","year":"2012","journal-title":"Clin. Dermatol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/wrr.12673","article-title":"Ointment vehicles regulate the wound-healing process by modifying the hyaluronan-rich matrix","volume":"26","author":"Murasawa","year":"2018","journal-title":"Wound Repair Regen."},{"key":"ref_57","first-page":"Cd012119","article-title":"Emollients and moisturisers for eczema","volume":"2","author":"Fedorowicz","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_58","first-page":"42","article-title":"Efficacy and tolerability of a repairing moisturizing cream containing amino-inositole and urea 10% in adults with chronic eczematous dermatitis of the hands","volume":"158","author":"Spigariolo","year":"2023","journal-title":"Ital. J. Dermatol. Venerol."},{"key":"ref_59","first-page":"657","article-title":"Advancement in benzoyl peroxide-based acne treatment: Methods to increase both efficacy and tolerability","volume":"8","author":"Fakhouri","year":"2009","journal-title":"J. Drugs Dermatol."},{"key":"ref_60","first-page":"s6","article-title":"Topical Vehicle Formulations in the Treatment of Acne","volume":"17","author":"Hoffman","year":"2018","journal-title":"J. Drugs Dermatol."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Menditto, E., Orlando, V., De Rosa, G., Minghetti, P., Musazzi, U.M., Cahir, C., Kurczewska-Michalak, M., Kardas, P., Costa, E., and Sousa Lobo, J.M. (2020). Patient Centric Pharmaceutical Drug Product Design-The Impact on Medication Adherence. Pharmaceutics, 12.","DOI":"10.3390\/pharmaceutics12010044"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"875","DOI":"10.36849\/JDD.6945","article-title":"Vehicle Formulation Impacts Tolerability and Patient Preference: Comparison of Tretinoin Branded Lotion and Generic Cream","volume":"21","author":"Draelos","year":"2022","journal-title":"J. Drugs Dermatol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1517\/17425247.2012.711756","article-title":"Topical drug delivery systems in dermatology: A review of patient adherence issues","volume":"9","author":"Tan","year":"2012","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s40257-017-0261-5","article-title":"Increasing Adherence with Topical Agents for Atopic Dermatitis","volume":"18","author":"Patel","year":"2017","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"341","DOI":"10.2340\/00015555-1304","article-title":"Elicitation and use of patients\u2019 preferences in the treatment of psoriasis: A systematic review","volume":"92","author":"Umar","year":"2012","journal-title":"Acta Derm. Venereol."},{"key":"ref_66","first-page":"75","article-title":"Needs and preferences of patients regarding atopic dermatitis care in the era of new therapeutic options: A qualitative study","volume":"315","author":"Devillers","year":"2023","journal-title":"Arch. Dermatol. Res."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1080\/09546634.2019.1675855","article-title":"Psoriasis patient preferences for topical drugs: A systematic review","volume":"32","author":"Svendsen","year":"2021","journal-title":"J. Dermatol. Treat."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s12272-010-2236-4","article-title":"Rheological evaluation of petroleum jelly as a base material in ointment and cream formulations: Steady shear flow behavior","volume":"33","author":"Park","year":"2010","journal-title":"Arch. Pharmacal Res."},{"key":"ref_69","first-page":"46","article-title":"Assessing attributes of topical vehicles for the treatment of acne, atopic dermatitis, and plaque psoriasis","volume":"94","author":"Eastman","year":"2014","journal-title":"Cutis"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"40","DOI":"10.12788\/cutis.0060","article-title":"Variations in preference for topical vehicles among demographic groups","volume":"106","author":"Figenshau","year":"2020","journal-title":"Cutis"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.1016\/j.jaad.2006.05.020","article-title":"African American and Caucasian patients\u2019 vehicle preference for the scalp","volume":"58","author":"Fisher","year":"2008","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1080\/09546634.2021.1944969","article-title":"Dermal sensitization, safety, tolerability, and patient preference of tazarotene 0.045% lotion from five clinical trials","volume":"33","author":"Kircik","year":"2022","journal-title":"J. Dermatolog. Treat."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/j.1365-2133.2005.07047.x","article-title":"Conjoint analysis: A novel, rigorous tool for determining patient preferences for topical antibiotic treatment for acne. A randomised controlled trial","volume":"154","author":"Kellett","year":"2006","journal-title":"Br. J. Dermatol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1080\/09546634.2020.1772452","article-title":"Patients\u2019 preferences of leave-on emollients: A survey on patients with atopic dermatitis","volume":"33","author":"Kunkiel","year":"2022","journal-title":"J. Dermatol. Treat."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1080\/09546634.2021.1940810","article-title":"Patient and caregiver preferences on treatment attributes for atopic dermatitis","volume":"33","author":"Ervin","year":"2022","journal-title":"J. Dermatol. Treat."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1001\/jamadermatol.2018.1096","article-title":"Adolescents\u2019 Perspectives on Atopic Dermatitis Treatment-Experiences, Preferences, and Beliefs","volume":"154","author":"Kosse","year":"2018","journal-title":"JAMA Dermatol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1001\/jamadermatol.2022.6045","article-title":"Values and Preferences of Patients and Caregivers Regarding Treatment of Atopic Dermatitis (Eczema): A Systematic Review","volume":"159","author":"Heen","year":"2023","journal-title":"JAMA Dermatol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1007\/s40257-021-00623-6","article-title":"Steroid Phobia: A Review of Prevalence, Risk Factors, and Interventions","volume":"22","author":"Contento","year":"2021","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.25251\/skin.2.supp.35","article-title":"Patient Concerns and Treatment Satisfaction in Patients Treated with Azelaic Acid Foam for Rosacea","volume":"2","author":"Williamson","year":"2018","journal-title":"SKIN J. Cutan. Med."},{"key":"ref_80","first-page":"97","article-title":"Patient Preferences and Therapeutic Satisfaction with Topical Agents for Rosacea: A Survey-Based Study","volume":"11","author":"Williamson","year":"2018","journal-title":"Am. Health Drug Benefits"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"743180","DOI":"10.3389\/fmed.2021.743180","article-title":"The Global, Regional, and National Burden of Psoriasis: Results and Insights From the Global Burden of Disease 2019 Study","volume":"8","author":"Damiani","year":"2021","journal-title":"Front. Med."},{"key":"ref_82","first-page":"304","article-title":"Calcipotriene 0.005%-Betamethasone Dipropionate 0.064% Ointment Versus Topical Suspension in the Treatment of Plaque Psoriasis: A Randomized Pilot Study of Patient Preference","volume":"94","author":"Sandoval","year":"2014","journal-title":"Cutis"},{"key":"ref_83","first-page":"327","article-title":"Patients with psoriasis prefer solution and foam vehicles: A quantitative assessment of vehicle preference","volume":"70","author":"Housman","year":"2002","journal-title":"Cutis"},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Hill, D., Farhangian, M.E., and Feldman, S.R. (2016). Increasing adherence to topical therapy in psoriasis through use of solution medication. Dermatol. Online J., 22.","DOI":"10.5070\/D3225030956"},{"key":"ref_85","first-page":"6","article-title":"Transition of Topical Therapy Formulation in Psoriasis: Insights from a Canadian Practice Reflective","volume":"27","author":"Adam","year":"2022","journal-title":"Skin Therapy Lett."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1080\/1744666X.2022.2110071","article-title":"A critical review of halobetasol propionate foam (0.05%) as a treatment option for adolescent plaque psoriasis","volume":"18","author":"Chung","year":"2022","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_87","first-page":"790","article-title":"Two Multicenter, Randomized, Double-Blind, Parallel Group Comparison Studies of a Novel Foam Formulation of Halobetasol Propionate, 0.05% vs Its Vehicle in Adult Subjects With Plaque Psoriasis","volume":"18","author":"Bhatia","year":"2019","journal-title":"J Drugs Dermatol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1007\/s13555-021-00600-1","article-title":"Beyond-Mild Psoriasis: A Consensus Statement on Calcipotriol and Betamethasone Dipropionate Foam for the Topical Treatment of Adult Patients","volume":"11","author":"Aschoff","year":"2021","journal-title":"Dermatol. Ther."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"e13185","DOI":"10.1111\/dth.13185","article-title":"A novel vehicle for the treatment of psoriasis","volume":"33","author":"Dattola","year":"2020","journal-title":"Dermatol. Ther."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/jdv.17734","article-title":"A pooled analysis of randomized, controlled, phase 3 trials investigating the efficacy and safety of a novel, fixed dose calcipotriene and betamethasone dipropionate cream for the topical treatment of plaque psoriasis","volume":"36","author":"Pinter","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1080\/09546634.2018.1544410","article-title":"Patient preferences for attributes of topical anti-psoriatic medicines","volume":"30","author":"Vasconcelos","year":"2019","journal-title":"J. Dermatol. Treat."},{"key":"ref_92","first-page":"AB50","article-title":"A novel foam vehicle is consistently preferred by patients for dermatologic conditions","volume":"64","author":"Weiss","year":"2011","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1111\/jdv.13749","article-title":"A systematic review on methods used to evaluate patient preferences in psoriasis treatments","volume":"30","author":"Gutknecht","year":"2016","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"508","DOI":"10.18203\/issn.2455-4529.IntJResDermatol20212327","article-title":"A study of clinical profile and quality of life in patients with scabies","volume":"7","author":"Nair","year":"2021","journal-title":"Int. J. Res. Dermatol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"231","DOI":"10.4103\/0378-6323.62961","article-title":"Topical treatment in vitiligo and the potential uses of new drug delivery systems","volume":"76","author":"Garg","year":"2010","journal-title":"Indian J. Dermatol. Venereol. Leprol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1080\/09546634.2018.1473837","article-title":"Patients preferences for different corticosteroid vehicles are highly variable","volume":"31","author":"Felix","year":"2020","journal-title":"J. Dermatol. Treat."},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Carvalho, M., and Almeida, I.F. (2022). The Role of Pharmaceutical Compounding in Promoting Medication Adherence. Pharmaceuticals, 15.","DOI":"10.3390\/ph15091091"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1468-3083.2005.01333.x","article-title":"The right dose in the right place: An overview of current prescription, instruction and application modalities for topical psoriasis treatments","volume":"19","author":"Savary","year":"2005","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_99","unstructured":"Paul, K., and Buxton, R.M.-J. (2013). ABC of Dermatology, BMJ Books. [5th ed.]."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/16\/4\/617\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:19:10Z","timestamp":1760123950000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/16\/4\/617"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,19]]},"references-count":99,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,4]]}},"alternative-id":["ph16040617"],"URL":"https:\/\/doi.org\/10.3390\/ph16040617","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,19]]}}}